 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Plasminogen activation
|
PDB id
|
|
|
|
1urk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Plasminogen activation
|
 |
|
Title:
|
 |
Solution structure of the amino terminal fragment of urokinase-type plasminogen activator
|
|
Structure:
|
 |
Plasminogen activator. Chain: a. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606
|
|
NMR struc:
|
 |
15 models
|
 |
|
Authors:
|
 |
A.P.Hansen,A.M.Petros,R.P.Meadows,D.G.Nettesheim,A.P.Mazar, E.T.Olejniczak,R.X.Xu,T.M.Pederson,J.Henkin,S.W.Fesik
|
Key ref:
|
 |
A.P.Hansen
et al.
(1994).
Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator.
Biochemistry,
33,
4847-4864.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
10-Jan-94
|
Release date:
|
08-May-95
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P00749
(UROK_HUMAN) -
Urokinase-type plasminogen activator
|
|
|
|
Seq: Struc:
|
 |
 |
 |
431 a.a.
130 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.21.73
- U-plasminogen activator.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Specific cleavage of Arg-|-Val bond in plasminogen to form plasmin.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
33:4847-4864
(1994)
|
|
PubMed id:
|
|
|
|
|
| |
|
Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator.
|
|
A.P.Hansen,
A.M.Petros,
R.P.Meadows,
D.G.Nettesheim,
A.P.Mazar,
E.T.Olejniczak,
R.X.Xu,
T.M.Pederson,
J.Henkin,
S.W.Fesik.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The amino-terminal fragment (ATF) of urokinase-type plasminogen activator is a
two domain protein which consists of a growth factor and a kringle domain. The
1H, 13C, and 15N chemical shifts of this protein have been assigned using
heteronuclear two- and three-dimensional NMR experiments on selective and
uniformly 15N- and 15N/13C-labeled protein isolated from mammalian cells that
overexpress the protein. The chemical shift assignments were used to interpret
the NOE data which resulted in a total of 1299 NOE restraints. The NOE
restraints were used along with 27 phi angle restraints and 21 hydrogen-bonding
restraints to produce 15 low energy structures. The individual domains in the
structures are highly converged, but the two domains are structurally
independent. The root mean square deviations (rmsd) between residues 11-46 in
the growth factor domain and the mean atomic coordinates were 0.99 +/- 0.2 for
backbone heavy atoms and 1.65 +/- 0.2 for all non-hydrogen atoms. For residues
55-130 in the kringle domain, the rmsd was 0.84 +/- 0.2 for backbone heavy atoms
and 1.42 +/- 0.2 for all non-hydrogen atoms. The overall structures of the
individual domains are very similar to the structures of homologous proteins.
However, important structural differences between the growth factor and other
homologous proteins were observed in the region which has been implicated in
binding the urokinase receptor which may explain, in part, why other growth
factors show no appreciable affinity for the urokinase receptor.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.Schaller,
and
S.S.Gerber
(2011).
The plasmin-antiplasmin system: structural and functional aspects.
|
| |
Cell Mol Life Sci, 68,
785-801.
|
 |
|
|
|
|
 |
D.Liu,
D.Overbey,
L.Watkinson,
and
M.F.Giblin
(2009).
Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).
|
| |
Bioconjug Chem, 20,
888-894.
|
 |
|
|
|
|
 |
V.V.Stepanova,
I.B.Beloglazova,
Y.G.Gursky,
R.S.Bibilashvily,
Y.V.Parfyonova,
and
V.A.Tkachuk
(2008).
Interaction between kringle and growth-factor-like domains in the urokinase molecule: possible role in stimulation of chemotaxis.
|
| |
Biochemistry (Mosc), 73,
252-260.
|
 |
|
|
|
|
 |
H.Gårdsvoll,
B.Gilquin,
M.H.Le Du,
A.Ménèz,
T.J.Jørgensen,
and
M.Ploug
(2006).
Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking.
|
| |
J Biol Chem, 281,
19260-19272.
|
 |
|
|
|
|
 |
Q.Huai,
A.P.Mazar,
A.Kuo,
G.C.Parry,
D.E.Shaw,
J.Callahan,
Y.Li,
C.Yuan,
C.Bian,
L.Chen,
B.Furie,
B.C.Furie,
D.B.Cines,
and
M.Huang
(2006).
Structure of human urokinase plasminogen activator in complex with its receptor.
|
| |
Science, 311,
656-659.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Huang,
A.P.Mazar,
G.Parry,
A.A.Higazi,
A.Kuo,
and
D.B.Cines
(2005).
Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
|
| |
Acta Crystallogr D Biol Crystallogr, 61,
697-700.
|
 |
|
|
|
|
 |
P.Llinas,
M.H.Le Du,
H.Gårdsvoll,
K.Danø,
M.Ploug,
B.Gilquin,
E.A.Stura,
and
A.Ménez
(2005).
Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
|
| |
EMBO J, 24,
1655-1663.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.Guthaus,
M.Bürgle,
N.Schmiedeberg,
S.Hocke,
A.Eickler,
M.D.Kramer,
C.G.Sweep,
V.Magdolen,
H.Kessler,
and
M.Schmitt
(2002).
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
|
| |
Biol Chem, 383,
207-216.
|
 |
|
|
|
|
 |
H.H.Petersen,
M.Hansen,
S.L.Schousboe,
and
P.A.Andreasen
(2001).
Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme.
|
| |
Eur J Biochem, 268,
4430-4439.
|
 |
|
|
|
|
 |
O.A.Ozhogina,
M.Trexler,
L.Bányai,
M.Llinás,
and
L.Patthy
(2001).
Origin of fibronectin type II (FN2) modules: structural analyses of distantly-related members of the kringle family idey the kringle domain of neurotrypsin as a potential link between FN2 domains and kringles.
|
| |
Protein Sci, 10,
2114-2122.
|
 |
|
|
|
|
 |
S.Rosenberg
(2001).
New developments in the urokinase-type plasminogen activator system.
|
| |
Expert Opin Ther Targets, 5,
711-722.
|
 |
|
|
|
|
 |
V.Magdolen,
M.Bürgle,
N.A.de Prada,
N.Schmiedeberg,
C.Riemer,
F.Schroeck,
J.Kellermann,
K.Degitz,
O.G.Wilhelm,
M.Schmitt,
and
H.Kessler
(2001).
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
|
| |
Biol Chem, 382,
1197-1205.
|
 |
|
|
|
|
 |
H.Gårdsvoll,
K.Danø,
and
M.Ploug
(1999).
Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis.
|
| |
J Biol Chem, 274,
37995-38003.
|
 |
|
|
|
|
 |
A.Muranyi,
B.E.Finn,
G.P.Gippert,
S.Forsén,
J.Stenflo,
and
T.Drakenberg
(1998).
Solution structure of the N-terminal EGF-like domain from human factor VII.
|
| |
Biochemistry, 37,
10605-10615.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.Bersch,
J.F.Hernandez,
D.Marion,
and
G.J.Arlaud
(1998).
Solution structure of the epidermal growth factor (EGF)-like module of human complement protease C1r, an atypical member of the EGF family.
|
| |
Biochemistry, 37,
1204-1214.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.Tolkatchev,
and
F.Ni
(1998).
Calcium binding properties of an epidermal growth factor-like domain from human thrombomodulin.
|
| |
Biochemistry, 37,
9091-9100.
|
 |
|
|
|
|
 |
M.Ploug,
S.Ostergaard,
L.B.Hansen,
A.Holm,
and
K.Danø
(1998).
Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
|
| |
Biochemistry, 37,
3612-3622.
|
 |
|
|
|
|
 |
M.Ploug
(1998).
Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
|
| |
Biochemistry, 37,
16494-16505.
|
 |
|
|
|
|
 |
S.Bieri,
A.R.Atkins,
H.T.Lee,
D.J.Winzor,
R.Smith,
and
P.A.Kroon
(1998).
Folding, calcium binding, and structural characterization of a concatemer of the first and second ligand-binding modules of the low-density lipoprotein receptor.
|
| |
Biochemistry, 37,
10994-11002.
|
 |
|
|
|
|
 |
U.H.Weidle,
and
B.König
(1998).
Urokinase receptor antagonists: novel agents for the treatment of cancer.
|
| |
Expert Opin Investig Drugs, 7,
391-403.
|
 |
|
|
|
|
 |
D.N.Marti,
C.K.Hu,
S.S.An,
P.von Haller,
J.Schaller,
and
M.Llinás
(1997).
Ligand preferences of kringle 2 and homologous domains of human plasminogen: canvassing weak, intermediate, and high-affinity binding sites by 1H-NMR.
|
| |
Biochemistry, 36,
11591-11604.
|
 |
|
|
|
|
 |
M.Bürgle,
M.Koppitz,
C.Riemer,
H.Kessler,
B.König,
U.H.Weidle,
J.Kellermann,
F.Lottspeich,
H.Graeff,
M.Schmitt,
L.Goretzki,
U.Reuning,
O.Wilhelm,
and
V.Magdolen
(1997).
Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
|
| |
Biol Chem, 378,
231-237.
|
 |
|
|
|
|
 |
M.Lohmeyer,
P.M.Harrison,
S.Kannan,
M.DeSantis,
N.J.O'Reilly,
M.J.Sternberg,
D.S.Salomon,
and
W.J.Gullick
(1997).
Chemical synthesis, structural modeling, and biological activity of the epidermal growth factor-like domain of human cripto.
|
| |
Biochemistry, 36,
3837-3845.
|
 |
|
|
|
|
 |
P.Franco,
C.Iaccarino,
F.Chiaradonna,
A.Brandazza,
C.Iavarone,
M.R.Mastronicola,
M.L.Nolli,
and
M.P.Stoppelli
(1997).
Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility.
|
| |
J Cell Biol, 137,
779-791.
|
 |
|
|
|
|
 |
C.E.White,
M.J.Hunter,
D.P.Meininger,
S.Garrod,
and
E.A.Komives
(1996).
The fifth epidermal growth factor-like domain of thrombomodulin does not have an epidermal growth factor-like disulfide bonding pattern.
|
| |
Proc Natl Acad Sci U S A, 93,
10177-10182.
|
 |
|
|
|
|
 |
M.Sunnerhagen,
G.A.Olah,
J.Stenflo,
S.Forsén,
T.Drakenberg,
and
J.Trewhella
(1996).
The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca2+ binding to the first EGF domain. A combined NMR-small angle X-ray scattering study.
|
| |
Biochemistry, 35,
11547-11559.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.Bork,
A.K.Downing,
B.Kieffer,
and
I.D.Campbell
(1996).
Structure and distribution of modules in extracellular proteins.
|
| |
Q Rev Biophys, 29,
119-167.
|
 |
|
|
|
|
 |
R.Tejero,
D.Bassolino-Klimas,
R.E.Bruccoleri,
and
G.T.Montelione
(1996).
Simulated annealing with restrained molecular dynamics using CONGEN: energy refinement of the NMR solution structures of epidermal and type-alpha transforming growth factors.
|
| |
Protein Sci, 5,
578-592.
|
 |
|
|
|
|
 |
S.Söhndel,
C.K.Hu,
D.Marti,
M.Affolter,
J.Schaller,
M.Llinás,
and
E.E.Rickli
(1996).
Recombinant gene expression and 1H NMR characteristics of the kringle (2 + 3) supermodule: spectroscopic/functional individuality of plasminogen kringle domains.
|
| |
Biochemistry, 35,
2357-2364.
|
 |
|
|
|
|
 |
V.Ellis
(1996).
Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
|
| |
J Biol Chem, 271,
14779-14784.
|
 |
|
|
|
|
 |
V.Magdolen,
P.Rettenberger,
M.Koppitz,
L.Goretzki,
H.Kessler,
U.H.Weidle,
B.König,
H.Graeff,
M.Schmitt,
and
O.Wilhelm
(1996).
Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
|
| |
Eur J Biochem, 237,
743-751.
|
 |
|
|
|
|
 |
G.Spraggon,
C.Phillips,
U.K.Nowak,
C.P.Ponting,
D.Saunders,
C.M.Dobson,
D.I.Stuart,
and
E.Y.Jones
(1995).
The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
|
| |
Structure, 3,
681-691.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.T.Stubbs,
and
W.Bode
(1994).
Coagulation factors and their inhibitors.
|
| |
Curr Opin Struct Biol, 4,
823-832.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|